Transgenic assays for mutations and cancer: Current status and future perspectives

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 400, Issue 1-2, 1998, Pages 337-354

  Vijg, Jan ^a   Van Steeg, Harry ^b  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Carcinogenicity; DNA repair gene; LacZ reporter gene; Mutagenicity; Risk estimation; Transgenic mouse model; Tumor suppressor gene

Indexed keywords

ANIMAL MODEL; ARTICLE; BIOASSAY; CARCINOGENESIS; CARCINOGENICITY; GENE MUTATION; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MUTAGEN TESTING; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASMS, EXPERIMENTAL;

EID: 0032565545     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00030-X     Document Type: Article

References (121)

1. [1] E.R. Fearon, B. Vogelstein, A genetic model for colorectal tumorigenesis, Cell 61 (1990) 759-767.
2. [2] L.A. Loeb, Endogenous carcinogenesis: molecular oncology into the twenty-first century, Cancer Res. 49 (1989) 5489-5496.
3. [3] B.N. Ames, L. Swirsky Gold, W.C. Willett, The causes and prevention of cancer, Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5258-5265.
4. [4] R.T. Bronson, Rate of occurrence of lesions in 20 inbred and hybrid genotypes of rats and mice sacrificed at 6-month intervals during the first years of life, in: D.E. Harrison (Ed.), Genetics of Aging II, Telford Press, Caldwell, NJ, 1990, pp. 280-358.
5. [5] R.T. Bronson, R.D. Lipman, Reduction in rate of occurrence of age-related lesions in dietary restricted laboratory mice, Growth Dev. Aging 55 (1991) 169-184.
6. [6] F.K. Ennever, T.J. Noonan, H.S. Rosenkranz, The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans, Mutagenesis 2 (1987) 73-78.
7. [7] B.N. Ames, L.S. Gold, Chemical carcinogenesis: too many rodent carcinogens, Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 7772-7776.
8. [8] B.N. Ames, L.S. Gold, Too many rodent carcinogens: mitogenesis increases mutagenesis, Science 249 (1990) 970-971, (Perspective).
9. [9] P.H. Abelson, Testing for carcinogens with rodents, Science 249 (1990) 1357, (Editorial).
10. [10] P.H. Abelson, Exaggerated carcinogenicity of chemicals, Science 256 (1992) 1609, (Editorial).
11. [11] S.S. Young, Do short-term tests predict rodent carcinogenicity?, Science 241 (1988) 1232-1233.
12. [12] A. Hay, Carcinogenesis: testing times for the tests, Nature 350 (1991) 555-556.
13. [13] B. Weinstein, Mitogenesis is only one factor in carcinogenesis, Science 251 (1991) 387-388.
14. [14] E. Farber, Cell proliferation as a major risk factor for cancer: a concept of doubtful validity, Cancer Res. 55 (1995) 3759-3762.
15. [15] B.N. Ames, F.D. Lee, W.E. Durston, An improved bacterial test system for the detection and classification of mutagens and carcinogens, Proc. Natl. Acad. Sci. U.S.A. 70 (1973) 782-786.
16. [16] D.M. Maron, B.N. Ames, Revised methods for the Salmonella mutagenicity test, Mutation Res. 113 (1983) 172-215.
17. [17] E. Zeiger, Carcinogenicity of mutagens: predictive capability of the Salmonella mutagenesis assay for rodent carcinogenicity, Cancer Res. 47 (1987) 1287-1296.
18. [18] R.W. Tennant, B.H. Margolin, M.D. Shelby, E. Zeiger, J.K. Haseman, J. Spalding, W. Caspary, M. Resnick, S. Stasiewicz, B. Anderson, R. Minor, Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays, Science 236 (1987) 933-941.
19. [19] M.J. Prival, V.C. Dunkel, Reevaluation of the mutagenicity and carcinogenicity of chemicals identified as 'false positives' in the Salmonella typhimurium mutagenicity assay, Environ. Mol. Mutagen. 13 (1989) 1-24.
20. [20] S.D. Morgenbesser, R.A. DePinho, Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer, Semin. Cancer Biol. 5 (1994) 21-36.
21. [21] R.D. Cardiff, E. Sinn, W. Muller, P. Leder, Transgenic oncogene mice. Tumor phenotype predicts genotype, Am. J. Pathol. 139 (1991) 495-501.
22. [22] G. Merlino, Transgenic mice as models for tumorigenesis, Cancer Invest. 12 (1994) 203-213.
23. [23] M. Breuer, R. Siebos, S. Verbeek, M. van Lohuizen, E. Wientjes, A. Berns, Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice, Nature 340 (1989) 61-63.
24. [24] C.J. Saris, J. Domen, A. Berns, The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG, EMBO J. 10 (1991) 655-664.
25. [25] M. Breuer, E. Wientjens, S. Verbeek, R. Siebos, A. Berns, Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras, Cancer Res. 51 (1991) 958-963.
26. [26] E.D. Kroese, P.M. Dortant, H. Van Steeg, C.Th.M. Van Oostrom, H.J. Van Kranen, A. De Vries, P.W. Wester, C.F. Van Kreijl, Use of E-pim-1 transgenic mice for short-term in vivo carcinogenicity testing: lymphoma induction by benzo[a]pyrene but not by TPA, Carcinogenesis 19 (1997) 975-980.
27. [27] I. Kryspin-Sorensen, A. Mortensen, E. Kristiansen, C.F. van Kreijl, R.H. Adamson, S.S. Thorgeirsson, Short-term carcinogenicity testing of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ) in Eμ-pim-1 transgenic mice, Carcinogenesis 17 (1996) 2221-2227.
28. [28] R.D. Storer, M.E. Cartwright, W.O. Cook, K.A. Soper, W.W. Nichols, Short-term Carcinogenesis bioassay of genotoxic procarcinogens in PIM transgenic mice, Carcinogenesis 16 (1995) 285-293.
29. [29] A. Leder, A. Kuo, R.D. Cardiff, E. Sinn, P. Leder, v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid, Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 9178-9182.
30. [30] L.A. Hansen, C.S. Trempus, J.F. Mahler, R.W. Tennant, Association of tumor development with increased cellular proliferation and transgene overexpression, but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice, Carcinogenesis 17 (1996) 1825-1833.
31. [31] R.E. Cannon, J.W. Spalding, C.S. Trempus, C.J. Szczesniak, K.M. Virgil, M.C. Humble, R.W. Tennant, Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice, Mol. Carcinog. 20 (1997) 108-114.
32. [32] D.M. Owens, J.W. Spalding, R.W. Tennant, R.C. Smart, Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin, Cancer Res. 55 (1995) 3171-3178.
33. [33] R.W. Tennant, J.E. French, J.W. Spalding, Identifying chemical carcinogens and assessing risk in short-term bioassays using transgenic mouse models, Environ. Health Perspect. 103 (1995) 942-950.
34. [34] A. Saitoh, M. Kimura, R. Takahashi, M. Yokoyama, T. Nomura, M. Izawa, T. Sekiya, S. Nishimura, M. Katsuki, Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes, Oncogene 5 (1990) 1195-1200.
35. [35] S. Yamamoto, K. Mitsumori, Y. Kodama, N. Matsunuma, S. Manabe, H. Okamiya, H. Suzuki, T. Fukuda, Y. Sakamaki, M. Sunaga, G. Nomura, K. Hioki, S. Wakana, T. Nomura, Y. Hayashi, Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice, Carcinogenesis 17 (1996) 101-107.
36. [36] K. Mitsumori, S. Wakana, S. Yamamoto, Y. Kodama, K. Yasuhara, T. Nomura, Y. Hayashi, R.R. Maronpot, Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors, Mol. Carcinog. 20 (1997) 298-307.
37. [37] A.J. Levine, p53, the cellular gatekeeper for growth and division, Cell 88 (1997) 323-331.
38. [38] L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery, J.S. Butel, A. Bradley, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature 356 (1992) 215-221.
39. [39] T. Jacks, L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, R.A. Weinberg, Tumor spectrum analysis in p53-mutant mice, Curr. Biol. 4 (1994) 1-7.
40. [40] D. Malking, F.P. Li, L.C. Strong, J.F. Fraumeni Jr., C.E. Nelson, D.H. Kim, J. Kassel, M.A. Gryka, F.Z. Bischoff, M.A. Tainsky et al., Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms, Science 250 (1990) 1233-1238.
41. [41] S. Srivastava, Z.Q. Zou, K. Pirollo, W. Blattner, E.H. Chang, Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome, Nature 348 (1990) 747-749.
42. [42] L.A. Donehower, The p53-deficient mouse: a model for basic and applied cancer studies, Semin. Cancer Biol. 7 (1996) 269-278.
43. [43] M. Harvey, M.J. McArthur, C.A. Montgomery, J.S. Butel, A. Bradley, L.A. Donehower, Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice, Nat. Genet. 5 (1993) 225-229.
44. [44] C.J. Kemp, L.A. Donehower, A. Bradley, A. Balmain, Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors, Cell 74 (1993) 813-822.
45. [45] C.J. Kemp, Hepatocarcinogenesis in p53-deficient mice, Mol. Carcinog. 12 (1995) 132-136.
46. [46] D.J. Jerry, J.S. Butel, L.A. Donehower, E.J. Paulson, C. Cochran, R.W. Wiseman, D. Medina, Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice, Mol. Carcinog. 9 (1994) 175-183.
47. [47] K. Savitsky, S. Sfez, D.A. Tagle, Y. Ziv, A. Sartiel, F.S. Collins, Y. Shiloh, G. Rotman, The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species, Hum. Mol. Genet. 4 (1995) 2025-2032.
48. [48] G. Rotman, Y. Shiloh, Ataxia-telangiectasia: is ATM a sensor of oxidative damage and stress?, Bioessays 19 (1997) 911-917.
49. [49] Y. Xu, T. Ashley, E.E. Brainerd, R.T. Bronson, M.S. Meyn, D. Baltimore, Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma, Genes Dev. 10 (1996) 2411-2422.
50. [50] C. Barlow, S. Hirotsune, R. Paylor, M. Liyanage, M. Eckhaus, F. Collins, Y. Shiloh, J.N. Crawley, T. Ried, D. Tagle, A. Wynshaw-Boris, Atm-deficient mice: a paradigm of ataxia telangiectasia, Cell 86 (1996) 159-171.
51. [51] R.S. Hawley, S.H. Friend, Strange bedfellows in even stranger places: the role of ATM in meiotic cells, lymphocytes, tumors, and its functional links to p53, Genes Dev. 10 (1996) 2383-2388.
52. [52] A.R. Clarke, E.R. Maandag, M. van Roon, N.M. van der Lugt, M. van der Valk, M.L. Hooper, A. Berns, H. te Riele, Requirement for a functional Rb-1 gene in murine development, Nature 359 (1992) 328-330.
53. [53] T. Jacks, A. Fazeli, E.M. Schmitt, R.T. Bronson, M.A. Goodell, R.A. Weinberg, Effects of an Rb mutation in the mouse, Nature 359 (1992) 295-300.
54. [54] R. Fodde, W. Edelmann, K. Yang, C. van Leeuwen, C. Carlson, B. Renault, C. Breukel, E. Alt, M. Lipkin, P.M. Khan, R. Kucherlapati, A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors, Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8969-8973.
55. [55] T. Jacks, T.S. Shih, E.M. Schmitt, R.T. Bronson, A. Bernards, R.A. Weinberg, Tumour predisposition in mice heterozygous for a targeted mutation in Nf1, Nat. Genet. 7 (1994) 353-361.
56. [56] C.I. Brannan, A.S. Perkins, K.S. Vogel, N. Ratner, M.L. Nordlund, S.W. Reid, A.M. Buchberg, N.A. Jenkins, L.F. Parada, N.G. Copeland, Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues, Genes Dev. 8 (1994) 1019-1029.
57. [57] A. Sancar, Mechanisms of DNA excision repair, Science 266 (1994) 1954-1956.
58. [58] K. Tanaka, N. Miura, I. Satokata, I. Miyamoto, M.C. Yoshida, Y. Satoh, S. Kondo, A. Yasui, H. Okayama, Y. Okada, Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain, Nature 348 (1990) 73-76.
59. [59] C.Th.M. Van Oostrom, A. de Vries, S.J. Verbeek, C.F. van Kreijl, H. van Steeg, Cloning and characterization of the mouse XPAC gene, Nucleic Acids Res. 22 (1994) 11-14.
60. [60] A. De Vries, C.Th.M. Van Oostrom, F.M.A. Hofhuis, P.M. Dortant, R.J.W. Berg, F.R. de Gruijl, P.W. Wester, C.F. Van Kreijl, P.J.A. Capel, H. Van Steeg, S.J. Verbeek, Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA, Nature 377 (1995) 169-173.
61. [61] H. Nakane, S. Takeuchi, S. Yuba, M. Saijo, Y. Nakatsu, H. Murai, Y. Nakatsuru, T. Ishikawa, S. Hirota, Y. Kitamura, Y. Kato, Y. Tsunoda, H. Miyauchi, T. Horio, T. Tokunaga, T. Matsunaga, O. Nikaido, Y. Nishimune, Y. Okada, K. Tanaka, High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A gene, Nature 377 (1995) 165-168.
62. [62] A.T. Sands, A. Abuin, A. Sanchez, C.J. Conti, A. Bradley, High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC, Nature 377 (1995) 162-165.
63. [63] J. McWhir, J. Selfridge, D.J. Harrison, S. Squires, D. Melton, Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning, Nat. Genet. 5 (1993) 217-224.
64. [64] Weeda, G., Donker, I., de Wit, J., Morreau, H., Janssens, R., Vissers, C.J., Niff, A., van Steeg, H., Bootsma, D., Hoeijmakers, J.H.J., Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Curr. Biol. (1997) 427-439.
65. [65] G.T.J. Van der Horst, H. van Steeg, R.J.W. Berg, A.J. van Gool, J. de Wit, G. Weeda, H. Morreau, R.B. Beems, C.F. van Kreijl, F.R. de Gruijl, D. Bootsma, J.H.J. Hoeijmakers, Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition, Cell 89 (1997) 425-435.
66. [66] S.S. Wallace, DNA damages processed by base excision repair: biological consequences, Int. J. Radiat. Biol. 66 (1994) 579-589.
67. [67] R.W. Sobol, J.K. Horton, R. Kuhn, H. Gu, R.K. Singhal, R. Prasad, K. Rajewsky, S.H. Wilson, Requirement of mammalian DNA polymerase-beta in base-excision repair, Nature 379 (1996) 183-186.
68. [68] B.P. Engelward, Weeda, G., Wyatt, M.D., Broekhof, J.L.M., de Wit, J., Donker, I., Allan, J.M., Golds, B., Hoeijmakers, J.H.J., Samson, L.D., (1997) Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 13087-13092.
69. [69] P. Modrich, Mismatch repair, genetic stability, and cancer, Science 266 (1994) 1959-1960.
70. [70] R. Fishel, M.K. Lescoe, M.R. Rao, N.G. Copeland, N.A. Jenkins, J. Garber, M. Kane, R. Kolodner, The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer, Cell 75 (1993) 1027-1038.
71. [71] N.C. Nicolaides, N. Papadopoulos, B. Liu, Y.F. Wei, K.C. Carter, S.M. Ruben, C.A. Rosen, W.A. Haseltine, R.D. Fleischmann, C.M. Fraser, M.D. Adams, J.C. Venter, M.G. Dunlop, S.R. Hamilton, G.M. Petersen, A. de la Chapelle, B. Vogelstein, K.W. Kinzler, Mutations of two PMS homologues in hereditary nonpolyposis colon cancer, Nature 371 (1994) 75-80.
72. [72] M. Perucho, Cancer of the microsatellite mutator phenotype, Biol. Chem. 377 (1996) 675-684.
73. [73] S.M. Baker, C.E. Bronner, L. Zhang, A.W. Plug, M. Robatzek, G. Warren, E.A. E.Elliott, J. Yu, T. Ashley, N. Arnheim, R.A. Havel, R.M. Liskay, Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis , Cell 82 (1995) 309-319.
74. [74] N. De Wind, M. Dekker, A. Van Rossum, M. Van der Valk, H. Te Riele, Mouse models for hereditary nonpolyposis colorectal cancer, Cancer Res. 58 (1998) 248-255.
75. [75] J. Essers, R.W. Hendriks, S.M. Swagemakers, C. Troelstra, J. de Wit, D. Bootsma, J.H. Hoeijmakers, R. Kanaar, Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination, Cell 89 (1997) 195-204.
76. [76] D.S. Lim, P. Hasty, A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53, Mol. Cell Biol. 16 (1996) 7133-7143.
77. [77] L.H. Thompson, Evidence that mammalian cells possess homologous recombinational repair pathways, Mutation Res. 363 (1996) 77-88.
78. [78] M.E.T. Dollé, H. Giese, C.L. Hopkins, H.-J. Martus, J.M. Hausdorff, J. Vijg, Rapid accumulation of genome rearrangements in liver but not in brain of old mice, Nat. Genet. 17 (1997) 431-434.
79. [79] H.J. Evans, Mutation cytogenetics: past, present and future, Mutation Res. 204 (1988) 355-363.
80. [80] J.A. Gossen, J.A. Vijg, Transgenic mice as model systems for studying gene mutations in vivo, Trends Genet. 9 (1993) 27-31.
81. [81] J.C. Mirsalis, J.A. Monforte, R.A. Winegar, Transgenic animal models for detection of in vivo mutations, Annu. Rev. Pharmacol. Toxicol. 35 (1995) 145-164.
82. [82] J.A. Gossen, J. Vijg, E. coli C: a convenient host strain for cloning highly methylated DNA, Nucleic Acids Res. 16 (1988) 9343.
83. [83] J.A. Gossen, W.J.F. de Leeuw, C.H.T. Tan, P.H.M. Lohman, F. Berends, D.L. Knook, E.C. Zwarthoff, J. Vijg, Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying gene mutations in vivo, Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 7971-7975.
84. - phage using a galactose-sensitive E. coli host, BioTechniques 14 (1993) 326-329.
85. [85] J. Vijg, G.R. Douglas, Transgenic mice for mutagenesis studies, in: G.P. Pfeifer (Ed.), Technologies for Detection of DNA Damage and Mutations, Part II, Plenum, New York, 1996, pp. 391-410.
86. [86] S.W. Kohler, G.S. Provost, P.L. Kretz, M.J. Dycaico, J.A. Sorge, J.M. Short, Development of a short-term in vivo mutagenesis assay: the effects of methylation on the recovery of a lambda shuttle vector from transgenic mice, Nucleic Acids Res. 18 (1990) 3007-3013.
87. [87] S.W. Kohler, G.S. Provost, A. Fieck, P.L. Kretz, W.O. Bullock, Sorge, D.L. Putman, J.M. Short, Spectra of spontaneous and mutagen-induced mutations in the LacI gene in transgenic mice, Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7958-7962.
88. [88] K.S. Lundberg, P.L. Kretz, G.S. Provost, J.M. Short, The use of selection in recovery of transgenic targets for mutation analysis, Mutation Res. 301 (1993) 99-105.
89. [89] N.J. Gorelick, Overview of mutation assays in transgenic mice for routine testing, Environ. Mol. Mutagen. 25 (1995) 218-230.
90. [90] H.V. Malling, J.G. Burkhart, Use of phi X174 as a shuttle vector for the study of in vivo mammalian mutagenesis, Mutation Res. 212 (1989) 11-21.
91. [91] P.M. Glazer, S.N. Sarkar, W.C. Summers, Detection and analysis of UV-induced mutations in mammalian cell DNA using a lambda phage shuttle vector, Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 1041-1044.
92. [92] E.G. Leach, E.J. Gunther, T.M. Yeasky, L.H. Gibson, T.L. Yang-Feng, P.M. Glazer, Frequent spontaneous deletions at a shuttle vector locus in transgenic mice, Mutagenesis 11 (1996) 49-56.
93. [93] J.A. Gossen, W.J.F. de Leeuw, A. Verwest, P.H.M. Lohman, J. Vijg, High somatic mutation frequencies in a LacZ transgene integrated on the mouse X-chromosome, Mutation Res. 250 (1991) 423-429.
94. [94] J.A. Gossen, W.J.F. de Leeuw, A.C. Molijn, J. Vijg, Plasmid rescue from transgenic mouse DNA using LacI represser protein conjugated to magnetic beads, BioTechniques 14 (1993) 624-629.
95. - plasmids, Nucleic Acids Res. 20 (1992) 3254.
96. [96] M.E.T.I. Boerrigter, M.E.T. Dollé, H.-J. Martus, J.A. Gossen, J. Vijg, Plasmid-based transgenic mouse model for studying in vivo mutations, Nature 377 (1995) 657-659.
97. [97] M.E.T. Dollé, H.-J. Martus, J.A. Gossen, M.E.T.I. Boerrigter, J. Vijg, Evaluation of a plasmid-based transgenic mouse model for detecting in vivo mutations, Mutagenesis 11 (1996) 111-118.
98. [98] Y. Gondo, N. Shioyama, M. Katsuki, A novel positive detection system of in vivo mutations in rpsL (strA) transgenic mice, Mutation Res. 360 (1996) 1-14.
99. [99] K.S. Tao, C. Urlando, J.A. Heddle, Comparison of somatic mutation in a transgenic versus host locus, Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10681-10685.
100. [100] T.R. Skopek, K.L. Kort, D.R. Marino, Relative sensitivity of the endogenous hprt gene and lacI transgene in ENU-treated Big Blue B6C3F1 mice, Environ. Mol. Mutagen. 26 (1995) 9-15.
101. [101] S.A. Grist, M. McCarron, A. Kutlaca, D.R. Turner, A.A. Morley, In vivo human somatic mutation: frequency and spectrum with age, Mutation Res. 266 (1992) 189-196.
102. [102] M. Akiyama, S. Kyoizumi, Y. Hirai, Y. Kusunoki, K.S. Iwamoto, N. Nakamura, Mutation frequency in human blood cells increases with age, Mutation Res. 338 (1995) 141-149.
103. [103] D. Kipling, H.E. Wilson, E.J. Thomson, M. Lee, J. Perry, S. Palmer, A. Ashworth, H.J. Cooke, Structural variation of the pseudoautosomal region between and within inbred mouse strains, Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 171-175.
104. [104] D.A. Evans, J.P. Burbach, F.W. van Leeuwen, Somatic mutations in the brain: relationship to aging?, Mutation Res. 338 (1995) 173-182.
105. [105] M. Gossen, S. Freundlieb, G. Bender, G. Muller, W. Hillen, H. Bujard, Transcriptional activation by tetracyclines in mammalian cells, Nucleic Acids Res. 268 (1995) 1766-1769.
106. [106] C. Cui, M.A. Wani, D. Wight, J. Kopchick, P.J. Stambrook, Reporter genes in transgenic mice, Transgenic Res. 3 (1994) 182-194.
107. [107] Z. Yu, C.S. Redfern, G.I. Fishman, Conditional transgene expression in the heart, Circ. Res. 79 (1996) 691-697.
108. [108] M.E. Boerrigter, J. Vijg, Sources of variability in mutant frequency determinations in different organs of lacZ plasmid-based transgenic mice: experimental features and statistical analysis, Environ. Mol. Mutagen. 29 (1997) 221-229.
109. [109] A. De Vries, C.Th.M. Van Oostrom, P.M. Dortant, R.B. Beems, C.F. Van Kreijl, P.J.A. Capel, H. Van Steeg, Spontaneous liver tumours and Benzo[a]pyrene-induced lymphomas in XPA-deficient mice, Mol. Carcinog. 19 (1997) 46-53.
110. [110] H. Nishino, A. Knoll, V. Buettner, C. Frisk, Y. Maruta, J. Haavik, S.S. Sommer, p53 wild-type and p53 nullizygous Big Blue transgenic mice have similar frequencies and patterns of observed mutation in liver, spleen and brain, Oncogene 11 (1995) 263-270.
111. [111] V.L. Buettner, H. Nishino, J. Haavik, A. Knoll, K. Hill, S.S. Sommer, Spontaneous mutation frequencies and spectra in p53 (+ / +) and p53 (-/ -) mice: a test of the 'guardian of the genome' hypothesis in the Big Blue(R) transgenic mouse mutation detection system, Mutation Res. 379 (1997) 13-20.
112. [112] A. De Vries, M.E.T. Dollé, J.L.M. Broekhof, A.J.J.A. Muller, E.D. Kroese, C.F. Van Kreijl, P.J.A. Capel, J. Vijg, H. Van Steeg, Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient / lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumor development, Carcinogenesis 18 (1997) 2327-2332.
113. [113] A.M. Lynch, N.J. Gooderham, A.R. Boobis, Organ distinctive mutagenicity in MutaMouse after short-term exposure to PhIP, Mutagenesis 11 (1996) 505-509.
114. [114] L. Narayanan, J.A. Fritzell, S.M. Baker, R.M. Liskay, P.M. Glazer, Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2, Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3122-3127.
115. [115] J.T. Wachsman, DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis, Mutation Res. 375 (1997) 1-8.
116. [116] D.W. Nebert, Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?, Am. J. Hum. Genet. 60 (1997) 265-271.
117. [117] F.P. Perera, Environment and cancer: who are susceptible?, Science 278 (1997) 1068-1073.
118. [118] P.H. Lohman, M.L. Mendelsohn, D.H. Moore, M.D. Waters, D.J. Brusick, J. Ashby, W.J. Lohman, International Commission for Protection Against Environmental Mutagens and Carcinogens. A method for comparing and combining short-term genotoxicity test data: the basic system, Mutation Res. 266 (1992) 7-25.
119. [119] J.G. Burkhart, H.V. Malling, Mutagenesis and transgenic systems: perspective from the mutagen N-ethyl-N-nitrosourea, Environ. Mol. Mutagen. 22 (1993) 1-6.
120. [120] B.N. Ames, L. Swirsky Gold, M.K. Shigenaga, Cancer prevention, rodent high-dose cancer tests, and risk assessment, Risk Anal. 16 (1996) 613-617.
121. [121] C. Eng, J. Vijg, Genetic testing: the problems and the promise, Nat. Biotechnol. 15 (1997) 422-426.